Loading clinical trials...
Loading clinical trials...
An Open-label, Multicenter, Phase 1/2 Study of JNJ-40346527, an FMS Inhibitor, in Subjects With Relapsed or Refractory Hodgkin Lymphoma
Conditions
Interventions
Phase 1, Cohort 1
Phase 1, Cohort 2
+3 more
Locations
4
France
Lille, France
Villejuif, France
Cologne, Germany
Würzburg, Germany
Start Date
July 17, 2012
Primary Completion Date
August 13, 2013
Completion Date
August 13, 2013
Last Updated
November 20, 2020
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions